General Information of Drug (ID: DMECVP9)

Drug Name
OP-0595 Drug Info
Synonyms
Nacubactam; 1452458-86-4; RG6080; RG-6080; UNII-832O37V7MZ; RO7079901; 832O37V7MZ; FPI-1459; 1452458-86-4 (free acid); RO-7079901; (1R,2S,5R)-2-((2-aminoethoxy)carbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate; Nacubactam [INN]; Nacubactam (USAN); Nacubactam [USAN:INN]; CHEMBL3989959; SCHEMBL15206610; SCHEMBL17975933; GTPL10833; MFCD28986228; OP0595; ZINC207610051; DB15353; SB17180; AS-35134; HY-109008; CS-0030506; D11329; Q27269383; (1R,2S,5R)-2-((2-Aminoethoxy)carbamoyl)-7-oxo- 1,6-diazabicyclo(3.2.1)octan-6-yl hydrogen sulfate; (2S,5R)-2-(2-Aminoethoxycarbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate; (2S,5R)-N-(2-Aminoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide; [(2S,5R)-2-(2-aminoethoxycarbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate; Sulfuric acid, mono((1R,2S,5R)-2-(((2-aminoethoxy)amino)carbonyl)-7-oxo-1,6-diazabicyclo(3.2.1)oct-6-yl) ester; Sulfuric acid, mono((1R,2S,5R)-2-(((2-aminoethoxy)amino)carbonyl)-7-oxo-1,6-diazabicyclo(3.2.1)oct-6-yl) ester, (-)-
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Phase 1 [1]
Cross-matching ID
PubChem CID
73386748
CAS Number
CAS 1452458-86-4
TTD Drug ID
DMECVP9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tazobactam DM3XNUI Appendicitis DB10 Approved [3]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [4]
CAZ AVI DMPG4OM Serious infection 1H0Z Phase 3 [5]
Enmetazobactam DMZKTYJ Urinary tract infection GC08 Phase 3 [6]
Vaborbactam DMDCFXJ Urinary tract infection GC08 Phase 3 [7]
MK-7655 DMLMV0O Bacterial infection 1A00-1C4Z Phase 2 [8]
CXL DM3JFZ2 Methicillin-resistant staphylococci infection 1A00-1A09 Phase 2 [9]
RASV-Sp DM4VTX6 Streptococcus infection 1B53 Phase 1 [10]
ME-1071 DMEMQ5J Bacterial infection 1A00-1C4Z Phase 1 [11]
VNRX-5133 DMNZ6XH Bacterial infection 1A00-1C4Z Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Staphylococcus Beta-lactamase (Stap-coc blaZ) TTHI19T BLAC_STAAU Inhibitor [2]

References

1 ClinicalTrials.gov (NCT02134834) A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595. U.S. National Institutes of Health.
2 OP0595, a new diazabicyclooctane: mode of action as a serine -lactamase inhibitor, antibiotic and -lactam 'enhancer'. J Antimicrob Chemother. 2015 Oct;70(10):2779-86.
3 Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9.
4 A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9.
5 NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7.
6 Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum--Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020 May 21;64(6):e00180-20.
7 Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17.
8 Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin . Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5.
9 Beta-Lactam Antibiotics Renaissance. Antibiotics. 2014, 3(2), 193-215.
10 WO patent application no. 2010,0456,20, Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae.
11 Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge. Curr Clin Pharmacol. 2014 Feb;9(1):27-38.
12 Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo--lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. J Med Chem. 2020 Mar 26;63(6):2789-2801.